Valneva: 26% increase in product sales in 2023
Product sales rose by 26% to 144.6 million euros over the past year, and excluding Covid-19 vaccine sales, they increased by 63% to 138.9 million.
For 2024, product sales are expected to be between 150 and 180 million euros, subject to the availability of Ixiaro and third-party products, as well as the performance of Ixchiq sales during the vaccine's launch year in the United States.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction